5,997 Shares in Insulet Corporation (NASDAQ:PODD) Acquired by Banque Cantonale Vaudoise

Key Points

• Banque Cantonale Vaudoise acquired 5,997 shares of Insulet Corporation (NASDAQ:PODD), valued at approximately $1,575,000, marking a significant investment in the medical instruments supplier.
• Insulet reported earnings of $1.02 per share for the last quarter, exceeding analysts' expectations of $0.81, and achieved a revenue of $569 million, which is a 28.8% increase compared to the previous year.
• Wall Street analysts remain optimistic about Insulet, with a consensus rating of "Moderate Buy" and an average price target of $321.00, following several upgrades from major brokerages.

Banque Cantonale Vaudoise acquired a new position in Insulet Corporation (NASDAQ:PODD - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 5,997 shares of the medical instruments supplier's stock, valued at approximately $1,575,000.

A number of other institutional investors have also recently bought and sold shares of PODD. Larson Financial Group LLC raised its stake in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 81 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Insulet during the fourth quarter valued at approximately $42,000. Ramirez Asset Management Inc. bought a new stake in Insulet in the 1st quarter worth approximately $53,000. Golden State Wealth Management LLC grew its holdings in Insulet by 553.1% during the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock valued at $55,000 after purchasing an additional 177 shares during the period. Finally, GW&K Investment Management LLC boosted its stake in shares of Insulet by 114.7% in the first quarter. GW&K Investment Management LLC now owns 249 shares of the medical instruments supplier's stock worth $65,000 after acquiring an additional 133 shares during the period.

Insider Buying and Selling at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president directly owned 23,180 shares in the company, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.39% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Truist Financial began coverage on shares of Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 price target for the company. Oppenheimer boosted their price objective on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Barclays upped their price objective on shares of Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. The Goldman Sachs Group began coverage on shares of Insulet in a research report on Friday, May 30th. They issued a "buy" rating and a $380.00 price target for the company. Finally, Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective on the stock in a research report on Tuesday, May 13th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $321.00.

Insulet Stock Up 0.7%

NASDAQ PODD traded up $2.05 on Monday, hitting $286.96. 355,506 shares of the stock traded hands, compared to its average volume of 762,026. The company has a current ratio of 4.47, a quick ratio of 3.63 and a debt-to-equity ratio of 1.21. The stock has a 50-day moving average of $302.39 and a 200 day moving average of $282.56. Insulet Corporation has a twelve month low of $173.00 and a twelve month high of $329.33. The company has a market capitalization of $20.20 billion, a P/E ratio of 51.64, a price-to-earnings-growth ratio of 2.54 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The firm had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. During the same period last year, the business posted $0.73 earnings per share. The firm's revenue for the quarter was up 28.8% on a year-over-year basis. As a group, analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.